Financials

Financials — What the Numbers Say

Zoetis prints the financial signature of a high-quality specialty pharma: $9.47B FY2025 revenue (+2.3%), 37.5% operating margin, 71.8% gross margin, and 25.6% return on invested capital — numbers that look more like a software franchise than a drug manufacturer. Cash conversion is real (FY2025 free cash flow of $2.28B, 85% of net income, 24.1% of revenue), and the balance sheet remains investment-grade even after a deliberate releveraging step in 2025 (net debt $6.93B, 1.72x EBITDA). The complication is on top of the income statement, not inside it: revenue growth has decelerated from a ~14% post-COVID run to ~2% in 2025, the share price has fallen from $125.82 at year-end to ~$80 in May 2026, and the market is now paying ~13x forward earnings for an asset that historically traded at 30–40x. The single financial metric that matters right now is operational revenue growth ex-FX and ex-MFA divestiture — if that holds at 5–7%, the franchise economics remain intact and the multiple compression is the opportunity; if it slides below 4%, the market is repricing the quality story permanently.

How to read this page. "Operating margin" is the share of every revenue dollar that survives cost of goods, SG&A, and R&D before tax and interest — Zoetis's 37.5% means it costs roughly 62 cents to deliver every dollar of sales. "Free cash flow" (FCF) is operating cash flow minus capex — the cash management can actually return or reinvest. "ROIC" is after-tax operating profit divided by debt-plus-equity — how much profit every dollar of capital deployed earns. "Net debt / EBITDA" is leverage adjusted for cash — how many years of pre-tax cash earnings it would take to repay debt.

1. Revenue, Margins, and Earnings Power

Zoetis has grown revenue from $2.76B in 2009 to $9.47B in 2025 — a 7.9% 16-year CAGR — but the shape of that growth is the story. The pre-COVID years grew 4–6% on price plus innovation. 2021 was a one-time +16% reflagging of the franchise as Apoquel/Cytopoint scaled and Simparica Trio launched. 2024–2025 reverted to the long-run 2–8% reported band.

Operating income has grown more than 6x since the 2010 spin-off setup year ($85M → $3,546M). Three patterns matter:

• Margin expansion was earned, not bought. Operating margin moved from 17% (FY2013) to 37.5% (FY2025) primarily through gross-margin lift (63% → 72%) as the mix shifted toward higher-margin companion-animal therapeutics. SG&A held tight at ~25% of revenue throughout, and R&D rose only modestly to 7.4%. There is no acquired-margin step-change — this is what a real pricing-power franchise looks like.
• 2015 was the cost-reset year, not a structural weakness. Operating margin temporarily compressed to 15.7% on restructuring; from FY2016 onward the franchise has compounded margin every year except FY2023.
• Recent margin still rising. Gross margin printed a new high of 71.8% in FY2025; operating margin set a new high of 37.5%. The deceleration is in growth, not profitability.

Quarterly Trajectory — The Reason the Market is Cautious

Q1 FY2026 revenue of $2,262M is up 2.9% versus Q1 FY2025 — the slowest reported growth since the IPO outside of FX shocks. The 4Q FY2025 print of $2,387M was actually flat vs Q4 FY2024 ($2,317M = +3%) and benefited from the previously-disclosed International fiscal-year alignment that pulled forward 2.5–3.5% of segment revenue into the quarter. Stripping that pull-forward, organic 4Q FY2025 was closer to flat. Operating income in 1Q FY2026 was $800M, +0.4% YoY — leverage is gone for the moment.

2. Cash Flow and Earnings Quality

Net income only matters if it converts to cash. Zoetis has cleared that bar consistently since 2017: operating cash flow has run above reported net income in 11 of the last 13 years, and free cash flow has averaged 88% of net income over the last five years.

The 2022–2023 conversion dip is the only flagged anomaly and it has a clean explanation visible in the working-capital lines: inventory ballooned from $1.92B (FY21) to $2.56B (FY23) as the company built safety stock during the post-COVID supply chain noise and as Librela/Solensia launches ramped. Days inventory outstanding climbed from 281 days in FY2021 to 350 days in FY2023. That cycle has now normalized — FY2024 and FY2025 conversion ratios are back at 92% and 85% of net income respectively, and inventory declined to $2.31B (FY24) before rising modestly to $2.43B in FY25 alongside revenue.

Major Cash-Flow Distortions

Three things stand out. Capex normalised — the company over-invested in capacity (manufacturing footprint, monoclonal-antibody plants for Librela) from 2019 to 2023 (capex peaked at $732M, or 8.6% of sales in FY2023) and has now stepped back to 6.6% of sales, helping FCF recover. SBC is small — $83M in FY2025 on $9.47B revenue is 0.9%, immaterial; this is not a software company hiding compensation through stock issuance. D&A exceeds capex ($487M vs $621M FY2025), but the gap is narrow and the asset base is real: PP&E is $3.97B and growing.

3. Balance Sheet and Financial Resilience

This is where the cleanest story tells itself in the data. Zoetis's balance sheet was levered at spin-off (FY2013 net debt/EBITDA of 3.0x as Pfizer loaded the entity with debt before the carveout), de-levered organically into 2017 (1.7x), absorbed the Abaxis acquisition in 2018 (2.2x), and then de-levered again through 2024 (0.9x) — only to deliberately re-lever in 2025 to fund a step-change in capital returns.

The 2025 jump from 0.89x to 1.72x net debt/EBITDA looks ugly on the chart, but it is the financial fingerprint of a deliberate capital-return decision, not distress:

• Long-term debt rose from $5.22B to $9.04B (a ~$3.85B new issuance).
• Cash rose only modestly from $1.99B to $2.31B.
• Net debt rose from $4.76B to $6.73B (+$2.0B).
• Shareholders' equity declined from $4.77B to $3.33B (–$1.44B) — because $3.24B was spent buying back stock and $0.89B paid in dividends, while only $2.67B of net income was generated.

Interest coverage actually improved to 16.0x EBIT despite the higher debt load — Zoetis termed-out new notes when its credit was strong. The Altman-Z-style read on this is unambiguous: this is a healthy investment-grade balance sheet that has been tactically re-geared, not a deteriorating one.

The standout balance-sheet line to monitor is inventory days at 324 — Zoetis carries roughly 11 months of cost of sales as inventory because biologics and vaccines require long lead times and global regulatory inventories. This is normal for animal-health and pharma manufacturing, but it ties up real working capital and amplifies the inventory write-down risk that Forensics flagged. Receivables (DSO at 56 days) and payables (DPO at 63 days) sit in normal pharma ranges.

4. Returns, Reinvestment, and Capital Allocation

ROIC has stepped from ~14% in 2014 to 25.6% in 2025, and ROA from 10% to 19% — every dollar of capital deployed earns materially more pre-tax operating profit today than a decade ago. ROE looks volatile because the equity base swings with buybacks and dividends; the 66% FY2025 print is mechanically inflated by the equity reduction. ROIC is the cleaner read, and at 25.6% it is one of the highest in pharma.

How Management Spends the Cash

The cumulative arc since 2018: shares reduced 12% (487M → 444M), EPS up 2.1x ($2.93 → $6.02), DPS up 4.0x ($0.50 → $2.00). The dividend has compounded faster than earnings (payout ratio rising from 17% in 2018 to 33% in 2025), and buybacks accelerated meaningfully in 2024–2025 — $1.86B in 2024 then $3.24B in 2025, the latter funded by $3.85B of new debt issuance.

5. Segment and Unit Economics

Zoetis reports on two geographic segments — U.S. and International — but the more economically useful split is companion animal vs livestock and within-companion the dermatology + parasiticide franchises.

Three points the segment tables reveal:

• The U.S. is the cash machine. U.S. segment margin is 67.5% pre-corporate and rising, vs International at 53.2%. The U.S. carries 54% of revenue but 60% of segment earnings — the U.S. companion-animal market (Apoquel, Cytopoint, Simparica Trio, Librela for dogs) is the highest-margin pool in the industry.
• Companion animal is doing all the work in 2025. Companion animal revenue grew 5% to $6.59B; livestock declined 5% to $2.76B (in part due to the MFA divestiture). Companion animal is now 70% of revenue, up from 64% in 2023.
• Livestock is mature and shrinking on a like-for-like basis. Strip out the MFA divestiture (~3 pts of company growth headwind) and livestock was approximately flat. This is the part of the business that exposes Zoetis to commodity-cycle and protein-pricing dynamics; companion animal is the moat.

6. Valuation and Market Expectations

The market is currently solving a quality-vs-growth puzzle. The franchise quality is unambiguous (37.5% operating margin, 25.6% ROIC, 24.1% FCF margin). What has compressed is the multiple it deserves now that growth has slowed to ~2–5%.

The story in one chart: P/E compressed from 57x at the FY2021 peak to 20.9x at FY2025 year-end. EV/EBITDA went from 37x to 15x. P/FCF went from 66x to 23x.

And it kept going. The May 2026 share price of ~$80 (vs $125.82 at year-end 2025) puts trailing P/E at approximately 13.3x on $6.03 TTM EPS — the lowest multiple Zoetis has traded at since the immediate aftermath of its 2013 IPO. EV/EBITDA on the same TTM numbers is roughly 9.4x, and FCF yield is approximately 6.7% at the current ~$33.9B market cap on $2.28B FCF.

What the Current Price Implies — A Simple Bear/Base/Bull

Zoetis at 13x earnings implicitly says: long-run growth is closer to 3% than 6%, and margins will not expand further. The franchise economics push against that.

The base case requires nothing heroic: stabilization at mid-single-digit growth and a P/E returning to the lower end of Zoetis's historical range. The bear case requires Apoquel/Cytopoint generic erosion or Librela safety overhang to permanently impair the franchise; the bull case requires Librela to resume its growth trajectory after the FDA label/safety scrutiny.

7. Peer Financial Comparison

This is the most decision-relevant table on the page. Zoetis sits between the diagnostics-quality leader (IDXX) and the troubled animal-health peer (ELAN). The valuation gap to IDXX is wide; the operational quality gap to ELAN is also wide.

The peer table tells two stories at once:

• Quality positioning is intact. ZTS's 37.5% operating margin and 24.1% FCF margin are higher than IDXX's (31.6% / 24.6%) on every line except FCF margin (a tie). ZTS's ROIC of 25.6% sits below IDXX's 44.2% — but IDXX runs an exceptionally light capital base. ZTS is dramatically more profitable than ELAN (negative op margin), PAHC (8.5%), and Virbac (16%).
• Valuation gap is the opportunity (or the warning). IDXX trades at 51.7x P/E and 36.3x EV/EBITDA; ZTS at 13.2x and 9.4x. That spread compresses if (a) ZTS growth re-accelerates so the market re-rates it back toward diagnostics-pure-play multiples, or (b) IDXX growth slows toward ZTS's pace and the IDXX premium contracts. The base case is some convergence — the historical spread between the two has averaged 1.7x EV/EBITDA, not the current ~4x.

Zoetis is the highest-quality, lowest-valued entry in the table — but the table is now structured around growth, not margin. The decision the buyer makes today is whether 2% revenue growth is a temporary digestion or a structural step-down.

8. What to Watch in the Financials

Closing Judgement

What the financials confirm. Zoetis is a high-quality franchise: 71.8% gross margin, 37.5% operating margin, 25.6% ROIC, and 85% cash conversion — none of which have deteriorated in the slowdown. Capital returns have accelerated meaningfully; buyback yield is at a company record. Balance sheet is investment-grade even after the 2025 re-leveraging.

What the financials contradict. The market price (~$80, 13x earnings) implies an "ex-growth, multiple-compression-justified" view. The income statement does not yet contain evidence of that — margins continue to expand, returns continue to climb, and cash conversion is normal. The discord is between the direction of profitability (still up) and the direction of growth (clearly down).

The first financial metric to watch is operational revenue growth ex-FX and ex-MFA divestiture in the next two quarterly prints (Q2 and Q3 FY2026). If that number prints 5–7% — meaning Librela stabilizes and dermatology + Simparica Trio continue to compound — the current valuation is too low for the quality and the multiple should re-rate. If it prints below 4% with no clear pipeline catalyst, the market is correctly repricing Zoetis as a maturing pharma at ~12–14x earnings rather than a 30x compounder.